Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping

Author:

Thomas Sherine E.1,Collins Patrick2,James Rory Hennell13ORCID,Mendes Vitor1,Charoensutthivarakul Sitthivut4ORCID,Radoux Chris5,Abell Chris4,Coyne Anthony G.4,Floto R. Andres67,von Delft Frank2389ORCID,Blundell Tom L.1ORCID

Affiliation:

1. Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1GA, UK

2. Diamond Light Source (DLS), Harwell Science and Innovation Campus, Didcot OX11 0DE, UK

3. Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK

4. Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK

5. The European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge CB10 1SD, UK

6. Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge CB23 3RE, UK

7. Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC-Laboratory of Molecular Biology, Cambridge CB2 0QH, UK

8. Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK

9. Department of Biochemistry, University of Johannesburg, Auckland Park 2006, South Africa

Abstract

Structure-guided drug discovery emerged in the 1970s and 1980s, stimulated by the three-dimensional structures of protein targets that became available, mainly through X-ray crystal structure analysis, assisted by the development of synchrotron radiation sources. Structures of known drugs or inhibitors were used to guide the development of leads. The growth of high-throughput screening during the late 1980s and the early 1990s in the pharmaceutical industry of chemical libraries of hundreds of thousands of compounds of molecular weight of approximately 500 Da was impressive but still explored only a tiny fraction of the chemical space of the predicted 10 40 drug-like compounds. The use of fragments with molecular weights less than 300 Da in drug discovery not only decreased the chemical space needing exploration but also increased promiscuity in binding targets. Here we discuss advances in X-ray fragment screening and the challenge of identifying sites where fragments not only bind but can be chemically elaborated while retaining their positions and binding modes. We first describe the analysis of fragment binding using conventional X-ray difference Fourier techniques, with Mycobacterium abscessus SAICAR synthetase (PurC) as an example. We observe that all fragments occupy positions predicted by computational hotspot mapping. We compare this with fragment screening at Diamond Synchrotron Light Source XChem facility using PanDDA software, which identifies many more fragment hits, only some of which bind to the predicted hotspots. Many low occupancy sites identified may not support elaboration to give adequate ligand affinity, although they will likely be useful in drug discovery as ‘warm spots’ for guiding elaboration of fragments bound at hotspots. We discuss implications of these observations for fragment screening at the synchrotron sources. This article is part of the theme issue ‘Fifty years of synchrotron science: achievements and opportunities’.

Funder

Botnar Fondation

Cystic Fibrosis Trust

Bill and Melinda Gates Foundation

Publisher

The Royal Society

Subject

General Physics and Astronomy,General Engineering,General Mathematics

Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3